Student & Trainee (ST)

P-090 - QUANTITATIVE MODELING AND SURVIVAL ANALYSIS IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS.

P-104 - BASELINE CORRECTION IN BIOEQUIVALENCE STUDIES FOR DRUG PRODUCTS CONTAINING AN ENDOGENOUS COMPOUND.

P-116 - IDENTIFYING THE CORE TRAINEE SKILLS AND PROGRAM CHARACTERISTICS OF SUCCESSFUL CLINICAL PHARMACOLOGY AND BIOMEDICAL T32 TRAINING PROGRAMS.

P-129 - MicroRNA SEQUENCING IN PATIENTS WITH CORONARY ARTERY DISEASE – CONSIDERATIONS FOR USE AS BIOMARKER FOR THROMBOTIC RISK.

P-176 - EFFICACY ENDPOINTS FOR THE 2020 FDA APPROVED NOVEL DRUGS.

P-213 - PACSIN2 AS A MODULATOR OF AUTOPHAGY AND THIOPURINE SENSITIVITY: IN VITRO EVALUATIONS IN LYMPHOID AND INTESTINAL CELLS.

PT-001 - COMPARATIVE ANALYSIS OF THE RB PATHWAY IN LEIOMYOSARCOMA.

PT-001 - COMPARATIVE ANALYSIS OF THE RB PATHWAY IN LEIOMYOSARCOMA.

PT-003 - CORONARY HEART DISEASE POLYGENIC RISK SCORE MODIFIES STATIN RELATIVE RISK REDUCTION FOR THE PRIMARY PREVENTION OF MYOCARDIAL INFARCTION IN A REAL-WORLD COHORT.

PT-003 - CORONARY HEART DISEASE POLYGENIC RISK SCORE MODIFIES STATIN RELATIVE RISK REDUCTION FOR THE PRIMARY PREVENTION OF MYOCARDIAL INFARCTION IN A REAL-WORLD COHORT.

PT-012 - PHARMACOGENOMIC SINGLE NUCLEOTIDE POLYMORPHISM (SNP) SCORES AS A TOOL TO PREDICT TOXICITY PHENOTYPES IN TREATMENT OF ACUTE CHILDHOOD LEUKEMIA (ALL).

PT-012 - PHARMACOGENOMIC SINGLE NUCLEOTIDE POLYMORPHISM (SNP) SCORES AS A TOOL TO PREDICT TOXICITY PHENOTYPES IN TREATMENT OF ACUTE CHILDHOOD LEUKEMIA (ALL).

PW-021 - IDENTIFYING BIOLOGICAL SIGNATURES OF NON-SUICIDAL SELF INJURY: A PHASE II, DOUBLE BLIND, RANDOMIZED, CONTROLLED TRIAL.